APA (7th ed.) Citation

T, L., W, Z., S, F., P, Y., G, O., & W, Q. (2026). Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy. Colloids and surfaces. B, Biointerfaces, 261, 115416. https://doi.org/10.1016/j.colsurfb.2026.115416

Chicago Style (17th ed.) Citation

T, Li, Zhuang W, Fan S, Yi P, Ouyang G, and Qian W. "Esterase-activatable Dimeric HDAC Inhibitor Nanotherapeutics for Enhanced Lymphoma Epigenetic Therapy." Colloids and Surfaces. B, Biointerfaces 261 (2026): 115416. https://doi.org/10.1016/j.colsurfb.2026.115416.

MLA (9th ed.) Citation

T, Li, et al. "Esterase-activatable Dimeric HDAC Inhibitor Nanotherapeutics for Enhanced Lymphoma Epigenetic Therapy." Colloids and Surfaces. B, Biointerfaces, vol. 261, 2026, p. 115416, https://doi.org/10.1016/j.colsurfb.2026.115416.